Find Faculty
Jian Jin, PhD
img_Jian Jin
PROFESSOR | Oncological Sciences
PROFESSOR | Pharmacological Sciences
PROFESSOR | Neuroscience
email
Research Topics
Cancer, Chromatin, Drug Design and Discovery, Epigenetics, Membrane Proteins/Channels, Neuroscience, Protein Degradation, Structural Biology
Multi-Disciplinary Training Area
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)
Discovery of Biased Ligands for G Protein-coupled Receptors
G protein-coupled receptors (GPCRs) signal not only via canonical pathways involving heterotrimeric large G proteins, but also via non-canonical G protein-independent interactions with other signaling proteins including beta-arrestins. Biased ligands of GPCRs preferentially engage either canonical or non-canonical signaling pathways and are extremely useful tools for elucidating the signal transduction pathways essential for both therapeutic actions and side-effects. The Jin lab has been actively engaged in discovering biased ligands of GPCRs for more than a decade.
Discovery of Selective Inhibitors for Histone Methyltransferases
Histone methyltransferases (HMTs, also known as protein methyltransferases (PMTs)) play critical roles in various human diseases including cancer. The Jin lab has taken a systematic approach to target HMTs for over a decade. By targeting the HMT substrate binding groove, cofactor binding site, and allosteric binding sites, the Jin lab has discovered numerous high quality selective inhibitors of HMTs, which have been widely used by the scientific community.
Discovery of Novel Degraders Targeting Oncogenic Proteins
The Jin lab is a leader in developing novel degraders targeting oncogenic proteins. Since 2014, the lab has discovered and characterized a number of first-in-class degraders using the PROTAC (proteolysis targeting chimera) and hydrophobic tagging technologies. Our degrader program has resulted in multiple patent applications filed by Mount Sinai.

BS, University of Science and Technology of China

PhD, Pennsylvania State University

Postdoc, Ohio State University

258
Publications

Selected Publications

Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor. Yan Xiong, Holger Greschik, Catrine Johansson, Ludwig Seifert, Vicki Gamble, Kwang Su Park, Vincent Fagan, Fengling Li, Irene Chau, Masoud Vedadi, Cheryl H. Arrowsmith, Paul Brennan, Oleg Fedorov, Manfred Jung, Gillian Farnie, Jing Liu, Udo Oppermann, Roland Schüle, Jian Jin. Journal of Medicinal Chemistry

Structurally Specific Z-DNA Proteolysis Targeting Chimera Enables Targeted Degradation of Adenosine Deaminase Acting on RNA 1. Zhen Wang, Dingpeng Zhang, Xing Qiu, Hiroyuki Inuzuka, Yan Xiong, Jing Liu, Li Chen, He Chen, Ling Xie, H. Ümit Kaniskan, Xian Chen, Jian Jin, Wenyi Wei. Journal of the American Chemical Society

Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2. Julia Velez, Brandon Dale, Kwang Su Park, H. Ümit Kaniskan, Xufen Yu, Jian Jin. European Journal of Medicinal Chemistry

View All Publications

Icahn (East) Building Floor 16th Room 16-20B

1425 Madison Ave

New York, NY 10029

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Jin during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Petra Pharma Corporation
  • Onsero Therapeutics
  • Accent Therapeutics, Inc.
  • Cullgen, Inc.
  • EpiCypher, Inc.

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Cullgen, Inc.

Founder/Co-Founder/Partner

  • Cullgen, Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.